SIGNIFICANT AGREEMENTS (Tables)

12 Months Ended

Dec. 31, 2018

The following table summarizes our total consolidated net revenues from collaborators, for the periods indicated, in thousands:

	Year Ended December 31,
Description	2018		2017		2016
Sanofi Genzyme	$	46,000	$	54,625	$	32,015
Vir Biotechnology		12,778		1,464		—
MDCO		2,789		30,217		11,220
Other		806		3,606		3,924
Total net revenues from collaborators	$	62,373	$	89,912	$	47,159

Balance and Change in Contract Liabilities Related to Collaboration Agreements

The following table presents the balance of our contract liabilities related to our collaboration agreements at December 31, 2018 and January 1, 2018, in thousands:

At December 31,

2018

At January 1,

2018

Contract liabilities:

Deferred revenues

3,954

16,570

During the year ended December 31, 2018, we recognized the following revenues as a result of the change in the contract liability balances related to our collaboration agreements, in thousands:

Revenue recognized in the period from:

Year Ended

December 31, 2018

Amounts included in contract liability at the beginning of the period

16,570

Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements

The following table provides the research and development expenses incurred by type that are directly attributable to our collaboration agreements by collaboration partner for the periods indicated, in thousands:

	Year Ended December 31,
	2018								2017								2016
	Sanofi Genzyme		Vir		MDCO		Ionis		Sanofi Genzyme		Vir		MDCO		Ionis		Sanofi Genzyme		Vir		MDCO		Ionis
Research and development
Clinical trial and manufacturing	$	36,600	$	7,272	$	1,664	$	—	$	174,901	$	1,134	$	5,421	$	—	$	150,179	$	—	$	1,211	$	—
External services		5,340		8,251		2		2,150		4,475		926		—		3,250		7,366		—		—		—
Other		1,279		548		203		1,097		5,327		—		106		—		3,035		—		64		525
Total research and development expenses	$	43,219	$	16,071	$	1,869	$	3,247	$	184,703	$	2,060	$	5,527	$	3,250	$	160,580	$	—	$	1,275	$	525

Prior Revenue Standard | ASU 2014-09 Revenue from Contracts with Customers

Revenue from Collaborators

The following table summarizes our total consolidated net revenues from collaborators, using the prior revenue standard, for the periods indicated, in thousands:

	Year Ended December 31,
Description	2018		2017		2016
Sanofi Genzyme	$	91,738	$	54,625	$	32,015
Vir Biotechnology		12,778		1,464		—
MDCO		7,184		30,217		11,220
Other		806		3,606		3,924
Total net revenues from collaborators	$	112,506	$	89,912	$	47,159